TNON Tenon Medical, Inc.
Financings ·
The investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement.
Holders exercised 572,179 existing warrants for cash and received new warrants for 858,269 shares at $5.02 per share. WallachBeth Capital acted as financial advisor, and the closing was expected on or about September 14, 2026.
Tenon repaid in full original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, issued March 11, 2026. The release names no noteholder or agent.
Tenon Medical agreed to sell 597,610 shares, or pre-funded warrants, to an institutional investor, with warrants for up to 1,058,517 more shares. WallachBeth Capital LLC is the exclusive placement agent.
Revenue rose 127% from a year earlier and gross margin reached 64%. Cash was $1.7 million at June 30, 2026, before a $4.2 million offering that closed on July 1.
The offering is priced at $0.38 per share and common warrants. WallachBeth Capital LLC is the sole placement agent, and part of the proceeds will repay convertible notes.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.9 million | $3.3 million |
| Research and development | $2.1 million | $2.6 million |
| Net income (loss) | -$12.6 million | -$13.7 million |
| Cash from operations | -$10.7 million | -$9.9 million |
| Cash and equivalents | $3.8 million | $6.5 million |
Our latest story on this, dated Oct 16, 2026: "Tenon Medical obtains investor waiver to increase at-the-market sales". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 9, 2026: "Tenon Medical repays convertible notes ahead of September 11 maturity". The story links the filing or release it is based on. Read the story.
Tenon Medical, Inc. trades under the ticker TNON on NASDAQ.
Tenon Medical, Inc. is listed on NASDAQ.
Our directory records Tenon Medical, Inc. under United States.
aibio.space lists Tenon Medical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$3.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Tenon Medical, Inc. reported a net loss of $12.6 million for the fiscal year ended Dec 31, 2025, and used $10.7 million of cash in operations, per its annual report to the SEC.
$2.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Tenon Medical, dated Oct 16, 2026: "Tenon Medical obtains investor waiver to increase at-the-market sales". The investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement. Source.
From our story of Sep 9, 2026: Its forward-looking statements list the ability to continue as a going concern, regaining and keeping Nasdaq listing compliance, and raising more capital on acceptable terms or at all as risks. Source.
Press Follow on this page to add Tenon Medical to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming Tenon Medical so far, in Company Updates, Debt Financing, Financings.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio